Target intelligence / Profile preview

F-box protein 38 (FBXO38)

Target
FBXO38
Molecular classification
F-box protein, Component of SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex, Ubiquitin ligase substrate receptor, Other (substrate adaptor in multi-protein complex)
01

Overview

F-box protein 38 (FBXO38) is a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex, responsible for the targeted ubiquitination and proteasomal degradation of select substrates. It was initially identified as a coactivator of the transcription factor KLF7 and is involved in neuronal development, spermatogenesis, and centromere integrity by targeting proteins ZXDA and ZXDB for degradation. FBXO38 has been reported to regulate immune checkpoint protein PD-1 in some studies; however, this role is disputed and considered unconfirmed by recent research. Mutations in the FBXO38 gene are linked to early-onset motor neuron diseases and other pathologies such as chronic inflammatory diseases. There are currently no drugs directly targeting FBXO38, and its role as a therapeutic target remains unestablished.

Other names
F-box only protein 38MoKASP329FLJ13962HMN2DHMND6modulator of KLF7 activity homologFBXO38
02

Mechanism of action

Not applicable—no specific drugs are documented to target FBXO38 in clinical or preclinical studies

03

Biological functions

Protein ubiquitination and degradation through the ubiquitin-proteasome pathwayRegulation of centromeric chromatin integrity via ZXDA/B protein degradationControl of Sertoli cell maturation and spermatogenesisRegulation of neuronal axon outgrowth and repair as a coactivator of KLF7Cytokinesis via stabilization of KIF20B with USP7Regulation of immune checkpoint proteins (controversial; see below)
04

Disease associations

Neurodegenerative disease (hereditary motor neuronopathy, distal spinal muscular atrophy)Cancer (potential role in tumor growth via PD-1 regulation and cGAS–STING pathway, but functional significance debated)Chronic inflammatory diseases (chronic periodontitis, chronic obstructive pulmonary disease)Disorders of sexual development (potential link to gender dysphoria)
05

Safety considerations

Loss or mutation associated with developmental delay, growth retardation, infertility, neurodegenerative symptoms, and altered immune responses
06

Interacting drugs

None currently known or clinically relevant
07

Biomarkers

Mutations or polymorphisms in FBXO38 as biomarkers for distal hereditary motor neuronopathy, chronic periodontitis, and COPD susceptibility

Beyond the preview

Go deeper on F-box protein 38 (FBXO38).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box protein 38 (FBXO38).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call